Vanderbilt Cardio-Oncology

Improved therapies have led to a spike in the number of people living with cancer, and today there are more than 15.5 million survivors in the United States. However, some of these therapies can cause toxicities to the heart, the vessels and the body’s metabolism. Read More

The 3 million prostate cancer survivors in the United States are likely to die from something other than cancer, thanks to early detection, effective treatment and the disease’s slow progression. Read More

Vanderbilt University Medical Center is hosting the first Global Cardio-Oncology Summit on Oct. 15-16, at the Hilton Nashville. The summit models a leading edge, interdisciplinary approach to cardio-oncology. Read More

Vanderbilt is embarking on a multi-disciplinary approach to understand how promising cancer treatments, specifically certain kinase inhibitors, affect the heart and kidneys. Read More

The Vanderbilt Cardio-Oncology program has fostered a collaborative relationship combining the expertise of cardiologists and oncologists to understand effects of cancer therapy on the heart. Read More

The Vanderbilt Cardio-Oncology program has fostered a special collaborative relationship combining the expertise of cardiologists and oncologists to understand the effects of cancer therapy on the heart. This type of collaboration is now helping to define the cardiovascular health of more than 14 million cancer survivors in the United States. Read More